IP Library Granted Patent US 8,138,314
Granted Patent B2
US 8,138,314 · App. 11/541,958 · Granted Mar 20, 2012

Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations

Assignees: Beth Israel Deaconess Medical Center, Inc.; Dana-Farber Cancer Institute; The General Hospital Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,138,314
App. No.
11/541,958
Granted
Mar 20, 2012
Kind
B2
Abstract

The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ + T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.

Claims (13)

1. A purified antibody, or a fragment or derivative thereof, that binds to the human CDR3 loop of a T cell receptor (TCR) α chain present on an invariant NKT cell, but does not substantially recognize and bind to other molecules in a biological sample which naturally includes other proteins or cells.

2. The purified antibody, fragment, or derivative of claim 1 that expands said invariant NKT cell.

3. The purified antibody, fragment, or derivative of claim 1 , wherein said antibody is a monoclonal antibody, or a fragment or derivative thereof.

4. The purified antibody of claim 1 , wherein said antibody is 6B11 (ATCC Deposit No. PTA-11305).

5. The purified antibody, fragment, or derivative of claim 1 , wherein said antibody, fragment, or derivative binds the amino acid sequence CVVSDRGST (SEQ ID NO:2).

6. The purified antibody, fragment, or derivative of claim 1 , wherein said antibody, fragment, or derivative has the same antigenic specificity as the 6B11 antibody.

7. The purified antibody, fragment, or derivative of claim 3 , wherein said monoclonal antibody is a humanized antibody, or a fragment or derivative thereof, wherein said fragment is selected from the group consisting of F(ab′) 2 , Fab, and scFv.

8. The purified antibody, fragment, or derivative of claim 7 , wherein said humanized antibody is a humanized form of 6B11, or a fragment or derivative thereof.

9. The purified antibody of claim 3 , wherein said antibody is a monoclonal antibody.

10. The purified antibody of claim 5 , wherein said antibody binds the amino acid sequence CVVSDRGST (SEQ ID NO:2).

11. The purified antibody of claim 6 , wherein said antibody has the same antigenic specificity as the 6B11 antibody.

12. The purified antibody of claim 8 , wherein said humanized antibody is a humanized form of 6B11.

13. The purified antibody of claim 7 , wherein said monoclonal antibody is a humanized antibody.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 8, 2016
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040576/0073 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT PREVIOUSLY RECORDED ON REEL 012442 FRAME 0307. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEES ARE "THE GENERAL HOSPITAL CORPORATION AND DANA-FARBER CANCER INSTITUTE," NOT "DANA-FARBER CANCER INSTITUTE". Recorded Feb 2, 2009
From: WILSON, SAMUEL B.
To: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL; DANA-FARBER CANCER INSTITUTE
Reel/Frame 022192/0708 →
Continuity (3)
Continuation 09885768 · Jun 19, 2001
Provisional Application 60212466 · Jun 19, 2000
Related Publication 20070160600A1 · Jul 12, 2007